AB0254 Dynamics of Disease Activity Scores During the First 12 Weeks Allow to Predict the Necessity in Combination Therapy with Methotrexate and Biologics Within T2T Strategy in Patients with Early and Established Rheumatoid Arthritis (Remarca Study)
| Autor: | E. L. Luchikhina, M. Kanonirova, N. Demidova, D.E. Karateev, Y. Olyunin, A.A. Novikov, Aleksandrova En, G. Loukina, Nasonov El |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty Combination therapy business.industry Inflammatory arthritis media_common.quotation_subject Immunology Treat to target medicine.disease General Biochemistry Genetics and Molecular Biology Surgery Disease activity Rheumatology Rheumatoid arthritis Internal medicine medicine Immunology and Allergy Methotrexate In patient business media_common medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 74:976.3-976 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background The Treat to Target (T2T) strategy in rheumatoid arthritis (RA) implies regular review of therapy in order to achieve the optimal outcome - remission or low disease activity (LDA). The majority of patients would require upgrade of therapy to drug combinations, including biologics. Prediction of the necessity of such upgrades is an important task for practitioners. Objectives To identify factors, indicating the necessity of biologics in RA patients, treated in compliance with T2T strategy. Methods The REMARCA study (Russian acronym: Russian InvEstigation of MethotrexAte and biologics in eaRly aCtive inflammatory Arthritis) included patients with early and established active RA, not treated previously with subcutaneous methotrexate (SC MT) injections and biologics. Totally 264 pts were included, 161 out of them (29 males, 132 females, 50,3% with disease duration Results The T2T targets by Month 12 were achieved in 120 (74,5%) pts, including LDA (3,3 p p =0,011), BlSDAI – 0,376 ( p =0,031), BlHAQ – 0,403 ( p =0,092), ΔDAS28 – 0,746 ( p p =0,003), ΔCDAI – 0,686 ( p =0,001). Therefore, disease activity scales showed the strongest predictive power, preferable cut off-points for prediction of the necessity in MT+BIO were: ΔDAS28 ≤1,3, ΔSDAI ≤14, ΔCDAI ≤11. Conclusions Dynamics in DAS28, SDAI and CDAI disease activity scores in 12 weeks after initiation of SC MT allow to predict the necessity of combination with biologics within 12 months in the treatment regimen in accordance to T2T strategy. Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|